Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122596) titled 'Short-course Treatment strategy for Tuberculosis in Patients with Diabetes Mellitus' on April 15.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shenzhen Third People's Hospital
Condition:
tuberculosis,diabetes mellitus
Intervention:
Expriment group A1:Participants classified as low treatment difficulty are randomized at baseline in a 1:1:1 ratio to Arm A1. They receive daily isoniazid, rifapentine 1200 mg, moxifloxacin, and pyrazinamide for the first 2 months, followed by daily isoniazid, rifapentine 1200 mg, and moxifloxacin for the next 2 months. The total treatment duration i...